Haemonetics

NYSE: HAE

$60.10USD

+0.16 (+0.28%)At close: Apr 27, 14:02 UTC

Open

$60.16

Prev. Close

$60.16

High

$60.16

Low

$60.10

Key Stats

Market Cap

$2.81B

Dividend Yield

–

P/E Ratio

16.0

EPS

2.56

Revenue

$1.37B

Avg. Volume

753.1K

TL;DR

Haemonetics surpasses CeriBell in revenue and profitability, while its VASCADE MVP XL achieves superior results with expanded FDA labeling for 17F venous sheaths.

Recently from Cashu

Haemonetics Innovates with VASCADE MVP XL, Enhancing Outcomes in Vascular Closure Technology

Haemonetics Corporation showcases innovation in medical technology with the recent release of clinical study results for its VASCADE MVP XL vascular closure system, which significantly outperforms its…

Cashu Markets·6h ago

Haemonetics Secures FDA Approval for Expanded VASCADE MVP XL Indication

Haemonetics Corporation recently secures a critical milestone as the U.S. Food and Drug Administration (FDA) grants approval for an expanded indication of its VASCADE MVP XL venous closure system. Thi…

Cashu Markets·4d ago

Haemonetics Gains FDA Approval for VASCADE MVP XL, Expanding Procedural Applications

Haemonetics Corporation has added a significant milestone to its portfolio with the recent approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of its VASCADE MVP XL ve…

Cashu Markets·7 days ago

Haemonetics Gains FDA Approval for Enhanced Vascular Closure System VASCADE MVP® XL

Haemonetics Expands Vascular Closure Capabilities with FDA Approval Haemonetics Corporation, a frontrunner in medical technology, secures a significant advancement in its vascular closure system with…

Cashu Markets·25 days ago